WATERTOWN, Mass. - Neumora Therapeutics, Inc. (NASDAQ:NMRA), a $1.7 billion market cap biopharmaceutical company focused on brain disease treatments, disclosed that its Phase 3 KOASTAL-1 Study of navacaprant did not meet the primary endpoint for treating major depressive disorder (MDD). According to InvestingPro data, the company maintains a FAIR financial health score despite being in the development stage. The study, which enrolled 383 adult patients, failed to show a statistically significant improvement in depressive symptoms as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 compared to placebo.
While the overall results did not meet expectations, an efficacy signal was observed in female participants, with a notable difference in their response to the drug compared to male participants. The company plans to further analyze these findings.
Navacaprant was shown to be generally well-tolerated, with a safety profile comparable to placebo. No serious adverse events were reported, and the rates of treatment discontinuation due to adverse events were low. The most common treatment-emergent adverse events (TEAEs) were headache and diarrhea.
Despite the KOASTAL-1 Study’s outcome, a significant proportion of patients who completed 6 weeks of navacaprant treatment chose to enroll in the KOASTAL-LT extension study. Neumora expects to provide additional updates on the navacaprant development program at the upcoming J.P. Morgan Healthcare Conference. InvestingPro data shows that two analysts have recently revised their earnings expectations downward, reflecting the study’s results.
The KOASTAL program includes three replicate Phase 3 studies, with the other two studies, KOASTAL-2 and KOASTAL-3, still ongoing. These studies aim to evaluate the efficacy and safety of navacaprant monotherapy in adult patients with moderate-to-severe MDD.
Navacaprant is a novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for MDD. It is designed to modulate dopamine and reward processing pathways, which are important for mood regulation. MDD affects over 21 million adults in the United States, with women being nearly twice as likely to experience depression. Current treatments often fail to achieve remission and can have negative side effects.
Neumora Therapeutics has a therapeutic pipeline of seven clinical and preclinical neuroscience programs targeting a range of brain diseases. The company’s mission is to redefine neuroscience drug development by advancing novel therapies for improved treatment outcomes. While not yet profitable, InvestingPro analysis reveals the company holds more cash than debt and maintains strong liquidity with current assets exceeding short-term obligations by nearly 11 times. For deeper insights into Neumora’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers, along with 6 additional ProTips and over 30 financial metrics.
This article is based on a press release statement from Neumora Therapeutics, Inc.
In other recent news, Neumora Therapeutics continues to be a focal point for investors and analysts. The company’s upcoming KOASTAL-1 Phase 3 trial results in Major Depressive Disorder (MDD) have been a significant topic of discussion. H.C. Wainwright has maintained its Buy rating on Neumora shares, expressing confidence in the potential of the upcoming trial results. Similarly, RBC Capital Markets has retained an Outperform rating, emphasizing the potential implications of a Johnson & Johnson clinical trial update for Neumora’s developments.
However, JPMorgan has downgraded Neumora from Overweight to Neutral, lowering the price target to $15.00, citing a balanced risk/reward outlook and potential downside without further data clarity. Neumora’s other clinical developments include NMRA-511 for Alzheimer’s disease-related agitation, and the KOASTAL-2 and -3 studies, expected to release data in the first half of 2025.
These recent developments reflect the evolving perspectives of analysts and the ongoing progress of Neumora’s clinical trials. It is noteworthy that despite the varying outlooks, all firms are closely monitoring the upcoming trial results, which could significantly impact Neumora’s future trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.